Van Oene Mark 4

What Happened

• Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), was granted a total of 1,500,000 share-based awards on 2026-02-27. The filing shows 500,000 Restricted Stock Units (RSUs) and 1,000,000 derivative share awards, each with an acquisition price of $0.00 (no cash paid at grant). These are awards/compensation, not open-market purchases or sales.

Key Details

• Transaction date: February 27, 2026; Form 4 filed March 3, 2026 (timely filing).
• Grant amounts & price: 500,000 RSUs @ $0.00; 1,000,000 derivative awards @ $0.00 (total granted = 1,500,000).
• Vesting:
  • 500,000 RSUs vest in equal annual installments on Feb 15 of 2027, 2028 and 2029 (subject to continued service).
  • 1,000,000 derivative awards vest in 36 equal monthly installments beginning March 27, 2026 (subject to continued service).
• Shares owned after transaction: Not specified in the filing.
• Remark: Reporting person serves as Chief Operating Officer.
• Derivative note: The 1,000,000 items are listed as derivative awards—rights to acquire shares upon vesting, not exercised shares at grant.

Context

• These grants are typical executive compensation/retention awards and do not represent an open-market purchase or sale. No immediate shares were sold or cashed out; any economic value depends on PACB’s stock price when/if the awards vest or are exercised.